nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR3—testicular cancer	0.382	0.69	CbGaD
Ponatinib—KIT—testicular cancer	0.171	0.31	CbGaD
Ponatinib—ABCB11—Vinblastine—testicular cancer	0.0296	0.134	CbGbCtD
Ponatinib—ABCG2—Dactinomycin—testicular cancer	0.0225	0.102	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—testicular cancer	0.0182	0.0826	CbGbCtD
Ponatinib—ABCG2—Carboplatin—testicular cancer	0.0151	0.0686	CbGbCtD
Ponatinib—CYP3A5—Ifosfamide—testicular cancer	0.0147	0.0667	CbGbCtD
Ponatinib—CYP2C8—Ifosfamide—testicular cancer	0.0141	0.0642	CbGbCtD
Ponatinib—ABCG2—Cisplatin—testicular cancer	0.0129	0.0586	CbGbCtD
Ponatinib—ABCG2—Etoposide—testicular cancer	0.0127	0.0576	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—testicular cancer	0.00865	0.0393	CbGbCtD
Ponatinib—ABCG2—Methotrexate—testicular cancer	0.00838	0.038	CbGbCtD
Ponatinib—ABCB1—Dactinomycin—testicular cancer	0.0081	0.0368	CbGbCtD
Ponatinib—CYP3A5—Etoposide—testicular cancer	0.00702	0.0319	CbGbCtD
Ponatinib—CYP2C8—Etoposide—testicular cancer	0.00675	0.0307	CbGbCtD
Ponatinib—CYP3A4—Ifosfamide—testicular cancer	0.00573	0.026	CbGbCtD
Ponatinib—KIT—seminiferous tubule of testis—testicular cancer	0.00572	0.12	CbGeAlD
Ponatinib—ABCB1—Vinblastine—testicular cancer	0.00507	0.023	CbGbCtD
Ponatinib—CYP2D6—Vinblastine—testicular cancer	0.00478	0.0217	CbGbCtD
Ponatinib—ABCB1—Cisplatin—testicular cancer	0.00465	0.0211	CbGbCtD
Ponatinib—ABCB1—Etoposide—testicular cancer	0.00457	0.0208	CbGbCtD
Ponatinib—ABCB1—Doxorubicin—testicular cancer	0.00312	0.0142	CbGbCtD
Ponatinib—CYP3A4—Vinblastine—testicular cancer	0.00304	0.0138	CbGbCtD
Ponatinib—ABCB1—Methotrexate—testicular cancer	0.00302	0.0137	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—testicular cancer	0.00294	0.0133	CbGbCtD
Ponatinib—CYP3A4—Etoposide—testicular cancer	0.00274	0.0124	CbGbCtD
Ponatinib—FGFR4—embryo—testicular cancer	0.0023	0.0484	CbGeAlD
Ponatinib—CYP3A4—Doxorubicin—testicular cancer	0.00187	0.00848	CbGbCtD
Ponatinib—Nilotinib—KIT—testicular cancer	0.00166	0.545	CrCbGaD
Ponatinib—FGFR3—embryo—testicular cancer	0.00157	0.033	CbGeAlD
Ponatinib—Imatinib—KIT—testicular cancer	0.00139	0.455	CrCbGaD
Ponatinib—FGFR4—Podofilox—Etoposide—testicular cancer	0.00136	0.582	CbGdCrCtD
Ponatinib—BCR—seminal vesicle—testicular cancer	0.00128	0.0268	CbGeAlD
Ponatinib—FGFR4—female gonad—testicular cancer	0.00127	0.0267	CbGeAlD
Ponatinib—FGFR4—testis—testicular cancer	0.00113	0.0237	CbGeAlD
Ponatinib—RET—embryo—testicular cancer	0.00108	0.0228	CbGeAlD
Ponatinib—FGFR3—gonad—testicular cancer	0.00107	0.0224	CbGeAlD
Ponatinib—FGFR2—embryo—testicular cancer	0.00103	0.0216	CbGeAlD
Ponatinib—TEK—embryo—testicular cancer	0.000986	0.0207	CbGeAlD
Ponatinib—BCR—gonad—testicular cancer	0.000923	0.0194	CbGeAlD
Ponatinib—FLT3—gonad—testicular cancer	0.000916	0.0193	CbGeAlD
Ponatinib—PDGFRA—embryo—testicular cancer	0.000893	0.0188	CbGeAlD
Ponatinib—SRC—embryo—testicular cancer	0.000876	0.0184	CbGeAlD
Ponatinib—FGFR4—lymph node—testicular cancer	0.000816	0.0172	CbGeAlD
Ponatinib—KDR—embryo—testicular cancer	0.000806	0.0169	CbGeAlD
Ponatinib—FGFR3—testis—testicular cancer	0.000769	0.0162	CbGeAlD
Ponatinib—KDR—seminal vesicle—testicular cancer	0.000757	0.0159	CbGeAlD
Ponatinib—BCR—female gonad—testicular cancer	0.00075	0.0158	CbGeAlD
Ponatinib—FLT3—female gonad—testicular cancer	0.000744	0.0157	CbGeAlD
Ponatinib—KIT—embryo—testicular cancer	0.000714	0.015	CbGeAlD
Ponatinib—KIT—seminal vesicle—testicular cancer	0.000671	0.0141	CbGeAlD
Ponatinib—FGFR1—female gonad—testicular cancer	0.000667	0.014	CbGeAlD
Ponatinib—BCR—testis—testicular cancer	0.000665	0.014	CbGeAlD
Ponatinib—FLT3—testis—testicular cancer	0.00066	0.0139	CbGeAlD
Ponatinib—ABL1—embryo—testicular cancer	0.000622	0.0131	CbGeAlD
Ponatinib—PDGFRA—gonad—testicular cancer	0.000606	0.0127	CbGeAlD
Ponatinib—LCK—female gonad—testicular cancer	0.000597	0.0126	CbGeAlD
Ponatinib—SRC—gonad—testicular cancer	0.000595	0.0125	CbGeAlD
Ponatinib—FGFR1—testis—testicular cancer	0.000592	0.0124	CbGeAlD
Ponatinib—ABL1—seminal vesicle—testicular cancer	0.000584	0.0123	CbGeAlD
Ponatinib—FGFR2—female gonad—testicular cancer	0.000567	0.0119	CbGeAlD
Ponatinib—TEK—female gonad—testicular cancer	0.000544	0.0114	CbGeAlD
Ponatinib—LCK—testis—testicular cancer	0.000529	0.0111	CbGeAlD
Ponatinib—RET—testis—testicular cancer	0.000529	0.0111	CbGeAlD
Ponatinib—ABCB11—testis—testicular cancer	0.000517	0.0109	CbGeAlD
Ponatinib—FGFR2—testis—testicular cancer	0.000503	0.0106	CbGeAlD
Ponatinib—PDGFRA—female gonad—testicular cancer	0.000493	0.0104	CbGeAlD
Ponatinib—KIT—gonad—testicular cancer	0.000485	0.0102	CbGeAlD
Ponatinib—SRC—female gonad—testicular cancer	0.000483	0.0102	CbGeAlD
Ponatinib—TEK—testis—testicular cancer	0.000482	0.0101	CbGeAlD
Ponatinib—BCR—lymph node—testicular cancer	0.000482	0.0101	CbGeAlD
Ponatinib—FLT3—lymph node—testicular cancer	0.000479	0.0101	CbGeAlD
Ponatinib—KDR—female gonad—testicular cancer	0.000444	0.00934	CbGeAlD
Ponatinib—PDGFRA—testis—testicular cancer	0.000437	0.00919	CbGeAlD
Ponatinib—FGFR1—lymph node—testicular cancer	0.000429	0.00902	CbGeAlD
Ponatinib—SRC—testis—testicular cancer	0.000429	0.00901	CbGeAlD
Ponatinib—ABL1—gonad—testicular cancer	0.000422	0.00887	CbGeAlD
Ponatinib—KDR—testis—testicular cancer	0.000394	0.00829	CbGeAlD
Ponatinib—KIT—female gonad—testicular cancer	0.000394	0.00828	CbGeAlD
Ponatinib—RET—lymph node—testicular cancer	0.000384	0.00807	CbGeAlD
Ponatinib—LCK—lymph node—testicular cancer	0.000384	0.00807	CbGeAlD
Ponatinib—ABCG2—seminal vesicle—testicular cancer	0.000368	0.00774	CbGeAlD
Ponatinib—TEK—lymph node—testicular cancer	0.00035	0.00735	CbGeAlD
Ponatinib—KIT—testis—testicular cancer	0.000349	0.00734	CbGeAlD
Ponatinib—ABL1—female gonad—testicular cancer	0.000343	0.00721	CbGeAlD
Ponatinib—PDGFRA—lymph node—testicular cancer	0.000317	0.00666	CbGeAlD
Ponatinib—SRC—lymph node—testicular cancer	0.000311	0.00653	CbGeAlD
Ponatinib—ABL1—testis—testicular cancer	0.000304	0.00639	CbGeAlD
Ponatinib—KDR—lymph node—testicular cancer	0.000286	0.00601	CbGeAlD
Ponatinib—KIT—lymph node—testicular cancer	0.000253	0.00532	CbGeAlD
Ponatinib—ABL1—lymph node—testicular cancer	0.00022	0.00463	CbGeAlD
Ponatinib—ABCG2—female gonad—testicular cancer	0.000216	0.00455	CbGeAlD
Ponatinib—CYP3A5—female gonad—testicular cancer	0.000201	0.00422	CbGeAlD
Ponatinib—CYP2C8—testis—testicular cancer	0.000197	0.00415	CbGeAlD
Ponatinib—ABCB1—embryo—testicular cancer	0.000193	0.00406	CbGeAlD
Ponatinib—ABCG2—testis—testicular cancer	0.000192	0.00403	CbGeAlD
Ponatinib—ABCB1—seminal vesicle—testicular cancer	0.000182	0.00382	CbGeAlD
Ponatinib—ABL1—Doxorubicin—Epirubicin—testicular cancer	0.000169	0.0724	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Epirubicin—testicular cancer	0.000169	0.0724	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Epirubicin—testicular cancer	0.000169	0.0724	CbGdCrCtD
Ponatinib—ABL1—Epirubicin—Doxorubicin—testicular cancer	0.000156	0.067	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Doxorubicin—testicular cancer	0.000156	0.067	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—testicular cancer	0.000156	0.067	CbGdCrCtD
Ponatinib—CYP2D6—female gonad—testicular cancer	0.000148	0.00312	CbGeAlD
Ponatinib—ABCG2—lymph node—testicular cancer	0.000139	0.00292	CbGeAlD
Ponatinib—CYP2D6—testis—testicular cancer	0.000131	0.00276	CbGeAlD
Ponatinib—ABCB1—gonad—testicular cancer	0.000131	0.00276	CbGeAlD
Ponatinib—ABCB1—female gonad—testicular cancer	0.000107	0.00224	CbGeAlD
Ponatinib—ABCB1—testis—testicular cancer	9.46e-05	0.00199	CbGeAlD
Ponatinib—ABCB1—lymph node—testicular cancer	6.85e-05	0.00144	CbGeAlD
Ponatinib—Erectile dysfunction—Methotrexate—testicular cancer	6.52e-05	0.000706	CcSEcCtD
Ponatinib—Dry skin—Doxorubicin—testicular cancer	6.51e-05	0.000704	CcSEcCtD
Ponatinib—Hyperhidrosis—Etoposide—testicular cancer	6.5e-05	0.000704	CcSEcCtD
Ponatinib—Pancreatitis—Epirubicin—testicular cancer	6.5e-05	0.000704	CcSEcCtD
Ponatinib—Hypokalaemia—Doxorubicin—testicular cancer	6.46e-05	0.000699	CcSEcCtD
Ponatinib—Angina pectoris—Epirubicin—testicular cancer	6.46e-05	0.000699	CcSEcCtD
Ponatinib—Breast disorder—Doxorubicin—testicular cancer	6.41e-05	0.000694	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	6.39e-05	0.000692	CcSEcCtD
Ponatinib—Decreased appetite—Cisplatin—testicular cancer	6.38e-05	0.000691	CcSEcCtD
Ponatinib—Diarrhoea—Dactinomycin—testicular cancer	6.36e-05	0.000688	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—testicular cancer	6.35e-05	0.000688	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—testicular cancer	6.35e-05	0.000687	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Cisplatin—testicular cancer	6.34e-05	0.000686	CcSEcCtD
Ponatinib—Vomiting—Bleomycin—testicular cancer	6.34e-05	0.000686	CcSEcCtD
Ponatinib—Infestation—Methotrexate—testicular cancer	6.32e-05	0.000684	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—testicular cancer	6.32e-05	0.000684	CcSEcCtD
Ponatinib—Pancytopenia—Epirubicin—testicular cancer	6.3e-05	0.000681	CcSEcCtD
Ponatinib—Rash—Bleomycin—testicular cancer	6.28e-05	0.00068	CcSEcCtD
Ponatinib—Pain—Cisplatin—testicular cancer	6.28e-05	0.00068	CcSEcCtD
Ponatinib—Dermatitis—Bleomycin—testicular cancer	6.28e-05	0.000679	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	6.26e-05	0.000678	CcSEcCtD
Ponatinib—Neutropenia—Epirubicin—testicular cancer	6.2e-05	0.000671	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—testicular cancer	6.18e-05	0.000668	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Epirubicin—testicular cancer	6.16e-05	0.000667	CcSEcCtD
Ponatinib—Stomatitis—Methotrexate—testicular cancer	6.16e-05	0.000666	CcSEcCtD
Ponatinib—Asthenia—Ifosfamide—testicular cancer	6.11e-05	0.000661	CcSEcCtD
Ponatinib—Paraesthesia—Etoposide—testicular cancer	6.04e-05	0.000654	CcSEcCtD
Ponatinib—Pruritus—Ifosfamide—testicular cancer	6.02e-05	0.000652	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—testicular cancer	6.01e-05	0.000651	CcSEcCtD
Ponatinib—Weight decreased—Epirubicin—testicular cancer	6e-05	0.000649	CcSEcCtD
Ponatinib—Dyspnoea—Etoposide—testicular cancer	6e-05	0.000649	CcSEcCtD
Ponatinib—Hyperglycaemia—Epirubicin—testicular cancer	5.98e-05	0.000647	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—testicular cancer	5.98e-05	0.000647	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—testicular cancer	5.97e-05	0.000647	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—testicular cancer	5.96e-05	0.000645	CcSEcCtD
Ponatinib—Pneumonia—Epirubicin—testicular cancer	5.95e-05	0.000644	CcSEcCtD
Ponatinib—Nausea—Bleomycin—testicular cancer	5.92e-05	0.000641	CcSEcCtD
Ponatinib—Infestation—Epirubicin—testicular cancer	5.91e-05	0.00064	CcSEcCtD
Ponatinib—Infestation NOS—Epirubicin—testicular cancer	5.91e-05	0.00064	CcSEcCtD
Ponatinib—Vomiting—Dactinomycin—testicular cancer	5.91e-05	0.00064	CcSEcCtD
Ponatinib—Rash—Dactinomycin—testicular cancer	5.86e-05	0.000634	CcSEcCtD
Ponatinib—Decreased appetite—Etoposide—testicular cancer	5.85e-05	0.000633	CcSEcCtD
Ponatinib—Diarrhoea—Ifosfamide—testicular cancer	5.83e-05	0.000631	CcSEcCtD
Ponatinib—Pancytopenia—Doxorubicin—testicular cancer	5.83e-05	0.000631	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Etoposide—testicular cancer	5.81e-05	0.000628	CcSEcCtD
Ponatinib—Body temperature increased—Cisplatin—testicular cancer	5.8e-05	0.000628	CcSEcCtD
Ponatinib—Fatigue—Etoposide—testicular cancer	5.8e-05	0.000628	CcSEcCtD
Ponatinib—Neuropathy peripheral—Epirubicin—testicular cancer	5.79e-05	0.000627	CcSEcCtD
Ponatinib—Stomatitis—Epirubicin—testicular cancer	5.76e-05	0.000624	CcSEcCtD
Ponatinib—Jaundice—Epirubicin—testicular cancer	5.76e-05	0.000624	CcSEcCtD
Ponatinib—Pain—Etoposide—testicular cancer	5.75e-05	0.000623	CcSEcCtD
Ponatinib—Constipation—Etoposide—testicular cancer	5.75e-05	0.000623	CcSEcCtD
Ponatinib—Urinary tract infection—Epirubicin—testicular cancer	5.75e-05	0.000622	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—testicular cancer	5.74e-05	0.000621	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—testicular cancer	5.7e-05	0.000617	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—testicular cancer	5.7e-05	0.000617	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—testicular cancer	5.67e-05	0.000614	CcSEcCtD
Ponatinib—Dizziness—Ifosfamide—testicular cancer	5.63e-05	0.00061	CcSEcCtD
Ponatinib—Hepatobiliary disease—Epirubicin—testicular cancer	5.59e-05	0.000605	CcSEcCtD
Ponatinib—Epistaxis—Epirubicin—testicular cancer	5.58e-05	0.000603	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—testicular cancer	5.55e-05	0.000601	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—testicular cancer	5.53e-05	0.000599	CcSEcCtD
Ponatinib—Nausea—Dactinomycin—testicular cancer	5.52e-05	0.000597	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—testicular cancer	5.5e-05	0.000595	CcSEcCtD
Ponatinib—Gastrointestinal pain—Etoposide—testicular cancer	5.5e-05	0.000595	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—testicular cancer	5.47e-05	0.000592	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—testicular cancer	5.47e-05	0.000592	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—testicular cancer	5.46e-05	0.000591	CcSEcCtD
Ponatinib—Vomiting—Ifosfamide—testicular cancer	5.41e-05	0.000586	CcSEcCtD
Ponatinib—Rash—Ifosfamide—testicular cancer	5.37e-05	0.000581	CcSEcCtD
Ponatinib—Dermatitis—Ifosfamide—testicular cancer	5.36e-05	0.000581	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—testicular cancer	5.36e-05	0.00058	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—testicular cancer	5.33e-05	0.000577	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—testicular cancer	5.33e-05	0.000577	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—testicular cancer	5.33e-05	0.000577	CcSEcCtD
Ponatinib—Body temperature increased—Etoposide—testicular cancer	5.32e-05	0.000575	CcSEcCtD
Ponatinib—Abdominal pain—Etoposide—testicular cancer	5.32e-05	0.000575	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—testicular cancer	5.32e-05	0.000575	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—testicular cancer	5.31e-05	0.000574	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—testicular cancer	5.3e-05	0.000574	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—testicular cancer	5.28e-05	0.000571	CcSEcCtD
Ponatinib—Asthenia—Cisplatin—testicular cancer	5.27e-05	0.00057	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—testicular cancer	5.26e-05	0.00057	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—testicular cancer	5.23e-05	0.000566	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—testicular cancer	5.21e-05	0.000564	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—testicular cancer	5.17e-05	0.00056	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—testicular cancer	5.16e-05	0.000558	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—testicular cancer	5.14e-05	0.000557	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—testicular cancer	5.11e-05	0.000554	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—testicular cancer	5.11e-05	0.000553	CcSEcCtD
Ponatinib—Chills—Methotrexate—testicular cancer	5.09e-05	0.000551	CcSEcCtD
Ponatinib—Nausea—Ifosfamide—testicular cancer	5.06e-05	0.000547	CcSEcCtD
Ponatinib—Diarrhoea—Cisplatin—testicular cancer	5.02e-05	0.000544	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—testicular cancer	5.01e-05	0.000542	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—testicular cancer	4.97e-05	0.000538	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—testicular cancer	4.96e-05	0.000537	CcSEcCtD
Ponatinib—Erythema—Methotrexate—testicular cancer	4.94e-05	0.000534	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—testicular cancer	4.94e-05	0.000534	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—testicular cancer	4.94e-05	0.000534	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—testicular cancer	4.92e-05	0.000533	CcSEcCtD
Ponatinib—Flushing—Epirubicin—testicular cancer	4.92e-05	0.000533	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—testicular cancer	4.91e-05	0.000531	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—testicular cancer	4.89e-05	0.000529	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—testicular cancer	4.84e-05	0.000524	CcSEcCtD
Ponatinib—Asthenia—Etoposide—testicular cancer	4.83e-05	0.000522	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—testicular cancer	4.83e-05	0.000522	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—testicular cancer	4.81e-05	0.000521	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—testicular cancer	4.78e-05	0.000518	CcSEcCtD
Ponatinib—Back pain—Methotrexate—testicular cancer	4.77e-05	0.000517	CcSEcCtD
Ponatinib—Chills—Epirubicin—testicular cancer	4.76e-05	0.000515	CcSEcCtD
Ponatinib—Pruritus—Etoposide—testicular cancer	4.76e-05	0.000515	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—testicular cancer	4.74e-05	0.000513	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—testicular cancer	4.73e-05	0.000512	CcSEcCtD
Ponatinib—Alopecia—Epirubicin—testicular cancer	4.69e-05	0.000508	CcSEcCtD
Ponatinib—Vomiting—Cisplatin—testicular cancer	4.67e-05	0.000505	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—testicular cancer	4.65e-05	0.000504	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—testicular cancer	4.65e-05	0.000503	CcSEcCtD
Ponatinib—Rash—Cisplatin—testicular cancer	4.63e-05	0.000501	CcSEcCtD
Ponatinib—Dermatitis—Cisplatin—testicular cancer	4.62e-05	0.000501	CcSEcCtD
Ponatinib—Erythema—Epirubicin—testicular cancer	4.62e-05	0.0005	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—testicular cancer	4.62e-05	0.0005	CcSEcCtD
Ponatinib—Diarrhoea—Etoposide—testicular cancer	4.6e-05	0.000498	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—testicular cancer	4.59e-05	0.000497	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—testicular cancer	4.56e-05	0.000494	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—testicular cancer	4.56e-05	0.000493	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—testicular cancer	4.56e-05	0.000493	CcSEcCtD
Ponatinib—Back pain—Epirubicin—testicular cancer	4.47e-05	0.000484	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—testicular cancer	4.45e-05	0.000482	CcSEcCtD
Ponatinib—Dizziness—Etoposide—testicular cancer	4.45e-05	0.000481	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—testicular cancer	4.44e-05	0.000481	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—testicular cancer	4.43e-05	0.000479	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—testicular cancer	4.42e-05	0.000478	CcSEcCtD
Ponatinib—Chills—Doxorubicin—testicular cancer	4.41e-05	0.000477	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—testicular cancer	4.39e-05	0.000475	CcSEcCtD
Ponatinib—Nausea—Cisplatin—testicular cancer	4.36e-05	0.000472	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—testicular cancer	4.35e-05	0.000471	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—testicular cancer	4.34e-05	0.00047	CcSEcCtD
Ponatinib—Cough—Methotrexate—testicular cancer	4.31e-05	0.000466	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—testicular cancer	4.3e-05	0.000466	CcSEcCtD
Ponatinib—Vomiting—Etoposide—testicular cancer	4.28e-05	0.000463	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—testicular cancer	4.27e-05	0.000463	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—testicular cancer	4.27e-05	0.000463	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—testicular cancer	4.27e-05	0.000462	CcSEcCtD
Ponatinib—Rash—Etoposide—testicular cancer	4.24e-05	0.000459	CcSEcCtD
Ponatinib—Dermatitis—Etoposide—testicular cancer	4.24e-05	0.000459	CcSEcCtD
Ponatinib—Headache—Etoposide—testicular cancer	4.21e-05	0.000456	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—testicular cancer	4.2e-05	0.000455	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—testicular cancer	4.2e-05	0.000455	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	4.17e-05	0.000452	CcSEcCtD
Ponatinib—LCK—Signaling by EGFR—FGFR3—testicular cancer	4.15e-05	0.000508	CbGpPWpGaD
Ponatinib—LCK—Downstream signal transduction—KIT—testicular cancer	4.15e-05	0.000508	CbGpPWpGaD
Ponatinib—Leukopenia—Epirubicin—testicular cancer	4.14e-05	0.000448	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—testicular cancer	4.13e-05	0.000448	CcSEcCtD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	4.13e-05	0.000506	CbGpPWpGaD
Ponatinib—LCK—Signaling by FGFR—KIT—testicular cancer	4.13e-05	0.000505	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR in Cancer—FGFR3—testicular cancer	4.11e-05	0.000504	CbGpPWpGaD
Ponatinib—Muscle spasms—Doxorubicin—testicular cancer	4.11e-05	0.000445	CcSEcCtD
Ponatinib—LCK—Signaling by ERBB2—KIT—testicular cancer	4.11e-05	0.000503	CbGpPWpGaD
Ponatinib—LCK—Signaling by PDGF—FGFR3—testicular cancer	4.1e-05	0.000501	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—INSL3—testicular cancer	4.09e-05	0.000501	CbGpPWpGaD
Ponatinib—LCK—DAP12 signaling—KIT—testicular cancer	4.09e-05	0.0005	CbGpPWpGaD
Ponatinib—SRC—Signaling by SCF-KIT—KIT—testicular cancer	4.08e-05	0.0005	CbGpPWpGaD
Ponatinib—Cough—Epirubicin—testicular cancer	4.03e-05	0.000436	CcSEcCtD
Ponatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	4.03e-05	0.000493	CbGpPWpGaD
Ponatinib—Vision blurred—Doxorubicin—testicular cancer	4.03e-05	0.000436	CcSEcCtD
Ponatinib—Infection—Methotrexate—testicular cancer	4e-05	0.000433	CcSEcCtD
Ponatinib—SRC—Downstream signal transduction—FGFR3—testicular cancer	4e-05	0.00049	CbGpPWpGaD
Ponatinib—Nausea—Etoposide—testicular cancer	4e-05	0.000432	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—testicular cancer	3.99e-05	0.000432	CcSEcCtD
Ponatinib—SRC—Signaling by FGFR—FGFR3—testicular cancer	3.98e-05	0.000487	CbGpPWpGaD
Ponatinib—SRC—Signaling by ERBB2—FGFR3—testicular cancer	3.96e-05	0.000485	CbGpPWpGaD
Ponatinib—KDR—Axon guidance—MMP2—testicular cancer	3.96e-05	0.000485	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by NGF—FGFR3—testicular cancer	3.96e-05	0.000484	CbGpPWpGaD
Ponatinib—Nervous system disorder—Methotrexate—testicular cancer	3.95e-05	0.000428	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—testicular cancer	3.95e-05	0.000428	CcSEcCtD
Ponatinib—PDGFRA—Signaling by NGF—FGFR3—testicular cancer	3.95e-05	0.000483	CbGpPWpGaD
Ponatinib—Thrombocytopenia—Methotrexate—testicular cancer	3.94e-05	0.000427	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—testicular cancer	3.93e-05	0.000426	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—testicular cancer	3.93e-05	0.000426	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—testicular cancer	3.91e-05	0.000424	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	3.91e-05	0.000423	CcSEcCtD
Ponatinib—FGFR2—Signaling by NGF—KIT—testicular cancer	3.9e-05	0.000477	CbGpPWpGaD
Ponatinib—Hyperhidrosis—Methotrexate—testicular cancer	3.89e-05	0.000422	CcSEcCtD
Ponatinib—FGFR1—Signaling Pathways—INSL3—testicular cancer	3.88e-05	0.000475	CbGpPWpGaD
Ponatinib—LCK—B Cell Activation—FGFR3—testicular cancer	3.88e-05	0.000475	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—INSL3—testicular cancer	3.87e-05	0.000474	CbGpPWpGaD
Ponatinib—Dry mouth—Epirubicin—testicular cancer	3.85e-05	0.000416	CcSEcCtD
Ponatinib—LCK—Signaling by FGFR in disease—KIT—testicular cancer	3.85e-05	0.000471	CbGpPWpGaD
Ponatinib—LCK—DAP12 interactions—KIT—testicular cancer	3.85e-05	0.000471	CbGpPWpGaD
Ponatinib—LCK—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	3.85e-05	0.000471	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—KITLG—testicular cancer	3.84e-05	0.00047	CbGpPWpGaD
Ponatinib—Leukopenia—Doxorubicin—testicular cancer	3.83e-05	0.000414	CcSEcCtD
Ponatinib—LCK—Signaling by EGFR—KIT—testicular cancer	3.81e-05	0.000467	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR in Cancer—KIT—testicular cancer	3.78e-05	0.000462	CbGpPWpGaD
Ponatinib—Oedema—Epirubicin—testicular cancer	3.77e-05	0.000408	CcSEcCtD
Ponatinib—LCK—Signaling by PDGF—KIT—testicular cancer	3.76e-05	0.00046	CbGpPWpGaD
Ponatinib—Infection—Epirubicin—testicular cancer	3.75e-05	0.000405	CcSEcCtD
Ponatinib—FGFR4—Disease—H2AFZ—testicular cancer	3.74e-05	0.000458	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—KITLG—testicular cancer	3.73e-05	0.000457	CbGpPWpGaD
Ponatinib—Cough—Doxorubicin—testicular cancer	3.73e-05	0.000404	CcSEcCtD
Ponatinib—BCR—Signaling Pathways—H2AFZ—testicular cancer	3.72e-05	0.000455	CbGpPWpGaD
Ponatinib—LCK—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	3.71e-05	0.000454	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR in disease—FGFR3—testicular cancer	3.71e-05	0.000454	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—STK11—testicular cancer	3.7e-05	0.000453	CbGpPWpGaD
Ponatinib—Nervous system disorder—Epirubicin—testicular cancer	3.7e-05	0.0004	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—testicular cancer	3.69e-05	0.0004	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—testicular cancer	3.69e-05	0.000399	CcSEcCtD
Ponatinib—SRC—Signaling by EGFR—FGFR3—testicular cancer	3.68e-05	0.00045	CbGpPWpGaD
Ponatinib—SRC—Downstream signal transduction—KIT—testicular cancer	3.67e-05	0.00045	CbGpPWpGaD
Ponatinib—Musculoskeletal discomfort—Methotrexate—testicular cancer	3.67e-05	0.000397	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—testicular cancer	3.66e-05	0.000396	CcSEcCtD
Ponatinib—SRC—Signaling by FGFR—KIT—testicular cancer	3.65e-05	0.000447	CbGpPWpGaD
Ponatinib—Hyperhidrosis—Epirubicin—testicular cancer	3.64e-05	0.000394	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—testicular cancer	3.64e-05	0.000394	CcSEcCtD
Ponatinib—SRC—Signaling by EGFR in Cancer—FGFR3—testicular cancer	3.64e-05	0.000446	CbGpPWpGaD
Ponatinib—Arthralgia—Doxorubicin—testicular cancer	3.64e-05	0.000394	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—testicular cancer	3.64e-05	0.000394	CcSEcCtD
Ponatinib—SRC—Signaling by ERBB2—KIT—testicular cancer	3.64e-05	0.000445	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by NGF—KIT—testicular cancer	3.63e-05	0.000445	CbGpPWpGaD
Ponatinib—BCR—Disease—FGFR3—testicular cancer	3.63e-05	0.000445	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—BCL10—testicular cancer	3.63e-05	0.000445	CbGpPWpGaD
Ponatinib—SRC—Signaling by PDGF—FGFR3—testicular cancer	3.63e-05	0.000444	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by NGF—KIT—testicular cancer	3.62e-05	0.000444	CbGpPWpGaD
Ponatinib—Paraesthesia—Methotrexate—testicular cancer	3.62e-05	0.000392	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	3.61e-05	0.000391	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—testicular cancer	3.59e-05	0.000389	CcSEcCtD
Ponatinib—LCK—B Cell Activation—KIT—testicular cancer	3.56e-05	0.000436	CbGpPWpGaD
Ponatinib—Dry mouth—Doxorubicin—testicular cancer	3.56e-05	0.000385	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—testicular cancer	3.55e-05	0.000384	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—testicular cancer	3.5e-05	0.000379	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—testicular cancer	3.49e-05	0.000378	CcSEcCtD
Ponatinib—LCK—Adaptive Immune System—BCL10—testicular cancer	3.49e-05	0.000427	CbGpPWpGaD
Ponatinib—Gastrointestinal disorder—Methotrexate—testicular cancer	3.48e-05	0.000376	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—testicular cancer	3.47e-05	0.000376	CcSEcCtD
Ponatinib—Infection—Doxorubicin—testicular cancer	3.47e-05	0.000375	CcSEcCtD
Ponatinib—Pain—Methotrexate—testicular cancer	3.45e-05	0.000373	CcSEcCtD
Ponatinib—FGFR4—Disease—KITLG—testicular cancer	3.44e-05	0.000422	CbGpPWpGaD
Ponatinib—Musculoskeletal discomfort—Epirubicin—testicular cancer	3.43e-05	0.000372	CcSEcCtD
Ponatinib—BCR—Signaling Pathways—KITLG—testicular cancer	3.42e-05	0.000419	CbGpPWpGaD
Ponatinib—Nervous system disorder—Doxorubicin—testicular cancer	3.42e-05	0.00037	CcSEcCtD
Ponatinib—LYN—Signaling Pathways—INSL3—testicular cancer	3.42e-05	0.000418	CbGpPWpGaD
Ponatinib—Thrombocytopenia—Doxorubicin—testicular cancer	3.42e-05	0.00037	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—testicular cancer	3.41e-05	0.000369	CcSEcCtD
Ponatinib—LCK—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	3.41e-05	0.000417	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR in disease—KIT—testicular cancer	3.4e-05	0.000417	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—KITLG—testicular cancer	3.4e-05	0.000416	CbGpPWpGaD
Ponatinib—Skin disorder—Doxorubicin—testicular cancer	3.39e-05	0.000367	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—testicular cancer	3.39e-05	0.000366	CcSEcCtD
Ponatinib—SRC—Signaling by EGFR—KIT—testicular cancer	3.37e-05	0.000413	CbGpPWpGaD
Ponatinib—Hyperhidrosis—Doxorubicin—testicular cancer	3.37e-05	0.000365	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—testicular cancer	3.36e-05	0.000364	CcSEcCtD
Ponatinib—SRC—Signaling by EGFR in Cancer—KIT—testicular cancer	3.34e-05	0.000409	CbGpPWpGaD
Ponatinib—BCR—Disease—KIT—testicular cancer	3.34e-05	0.000408	CbGpPWpGaD
Ponatinib—SRC—Signaling by PDGF—KIT—testicular cancer	3.33e-05	0.000408	CbGpPWpGaD
Ponatinib—Dyspepsia—Epirubicin—testicular cancer	3.32e-05	0.000359	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—testicular cancer	3.29e-05	0.000357	CcSEcCtD
Ponatinib—SRC—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	3.28e-05	0.000402	CbGpPWpGaD
Ponatinib—Decreased appetite—Epirubicin—testicular cancer	3.28e-05	0.000355	CcSEcCtD
Ponatinib—FGFR2—Innate Immune System—KITLG—testicular cancer	3.26e-05	0.000399	CbGpPWpGaD
Ponatinib—Gastrointestinal disorder—Epirubicin—testicular cancer	3.25e-05	0.000352	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—testicular cancer	3.25e-05	0.000352	CcSEcCtD
Ponatinib—FGFR3—Innate Immune System—KIT—testicular cancer	3.23e-05	0.000396	CbGpPWpGaD
Ponatinib—Constipation—Epirubicin—testicular cancer	3.22e-05	0.000349	CcSEcCtD
Ponatinib—Pain—Epirubicin—testicular cancer	3.22e-05	0.000349	CcSEcCtD
Ponatinib—SRC—Innate Immune System—BCL10—testicular cancer	3.22e-05	0.000394	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—KITLG—testicular cancer	3.2e-05	0.000392	CbGpPWpGaD
Ponatinib—Body temperature increased—Methotrexate—testicular cancer	3.18e-05	0.000345	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—testicular cancer	3.18e-05	0.000345	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	3.18e-05	0.000344	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—testicular cancer	3.16e-05	0.000341	CcSEcCtD
Ponatinib—FGFR2—Immune System—BCL10—testicular cancer	3.15e-05	0.000385	CbGpPWpGaD
Ponatinib—Paraesthesia—Doxorubicin—testicular cancer	3.13e-05	0.000339	CcSEcCtD
Ponatinib—FGFR2—Adaptive Immune System—KITLG—testicular cancer	3.13e-05	0.000383	CbGpPWpGaD
Ponatinib—Dyspnoea—Doxorubicin—testicular cancer	3.11e-05	0.000337	CcSEcCtD
Ponatinib—FGFR3—Adaptive Immune System—KIT—testicular cancer	3.1e-05	0.00038	CbGpPWpGaD
Ponatinib—KIT—Immune System—BCL10—testicular cancer	3.09e-05	0.000378	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—BCL10—testicular cancer	3.09e-05	0.000378	CbGpPWpGaD
Ponatinib—Gastrointestinal pain—Epirubicin—testicular cancer	3.08e-05	0.000334	CcSEcCtD
Ponatinib—KIT—Adaptive Immune System—KITLG—testicular cancer	3.07e-05	0.000376	CbGpPWpGaD
Ponatinib—Dyspepsia—Doxorubicin—testicular cancer	3.07e-05	0.000332	CcSEcCtD
Ponatinib—FGFR1—Innate Immune System—KITLG—testicular cancer	3.04e-05	0.000372	CbGpPWpGaD
Ponatinib—Decreased appetite—Doxorubicin—testicular cancer	3.03e-05	0.000328	CcSEcCtD
Ponatinib—PDGFRA—Innate Immune System—KITLG—testicular cancer	3.03e-05	0.000371	CbGpPWpGaD
Ponatinib—SRC—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	3.02e-05	0.000369	CbGpPWpGaD
Ponatinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	3.01e-05	0.000326	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—testicular cancer	3.01e-05	0.000326	CcSEcCtD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	3e-05	0.000367	CbGpPWpGaD
Ponatinib—Constipation—Doxorubicin—testicular cancer	2.98e-05	0.000323	CcSEcCtD
Ponatinib—Pain—Doxorubicin—testicular cancer	2.98e-05	0.000323	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—testicular cancer	2.98e-05	0.000323	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—testicular cancer	2.98e-05	0.000323	CcSEcCtD
Ponatinib—FGFR1—Immune System—BCL10—testicular cancer	2.93e-05	0.000359	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—BCL10—testicular cancer	2.93e-05	0.000358	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—KITLG—testicular cancer	2.92e-05	0.000357	CbGpPWpGaD
Ponatinib—FGFR1—Axon guidance—MMP2—testicular cancer	2.91e-05	0.000357	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—KITLG—testicular cancer	2.91e-05	0.000356	CbGpPWpGaD
Ponatinib—Asthenia—Methotrexate—testicular cancer	2.89e-05	0.000313	CcSEcCtD
Ponatinib—LCK—Signaling by NGF—FGFR3—testicular cancer	2.85e-05	0.000349	CbGpPWpGaD
Ponatinib—Gastrointestinal pain—Doxorubicin—testicular cancer	2.85e-05	0.000309	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—testicular cancer	2.85e-05	0.000308	CcSEcCtD
Ponatinib—KDR—Developmental Biology—MMP2—testicular cancer	2.83e-05	0.000346	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—INSL3—testicular cancer	2.8e-05	0.000343	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—FGFR3—testicular cancer	2.77e-05	0.000339	CbGpPWpGaD
Ponatinib—FGFR3—Disease—H2AFZ—testicular cancer	2.77e-05	0.000339	CbGpPWpGaD
Ponatinib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	2.77e-05	0.000339	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—KITLG—testicular cancer	2.76e-05	0.000338	CbGpPWpGaD
Ponatinib—Abdominal pain—Doxorubicin—testicular cancer	2.76e-05	0.000298	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—testicular cancer	2.76e-05	0.000298	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—testicular cancer	2.76e-05	0.000298	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—testicular cancer	2.7e-05	0.000293	CcSEcCtD
Ponatinib—LYN—Innate Immune System—KITLG—testicular cancer	2.67e-05	0.000327	CbGpPWpGaD
Ponatinib—Pruritus—Epirubicin—testicular cancer	2.67e-05	0.000289	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—testicular cancer	2.66e-05	0.000288	CcSEcCtD
Ponatinib—ABL1—Innate Immune System—KITLG—testicular cancer	2.66e-05	0.000326	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—H2AFZ—testicular cancer	2.62e-05	0.000321	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—KIT—testicular cancer	2.62e-05	0.000321	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—STK11—testicular cancer	2.61e-05	0.000319	CbGpPWpGaD
Ponatinib—LYN—Immune System—BCL10—testicular cancer	2.58e-05	0.000316	CbGpPWpGaD
Ponatinib—Diarrhoea—Epirubicin—testicular cancer	2.58e-05	0.000279	CcSEcCtD
Ponatinib—ABL1—Immune System—BCL10—testicular cancer	2.57e-05	0.000314	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—KITLG—testicular cancer	2.57e-05	0.000314	CbGpPWpGaD
Ponatinib—LYN—Axon guidance—MMP2—testicular cancer	2.56e-05	0.000314	CbGpPWpGaD
Ponatinib—Vomiting—Methotrexate—testicular cancer	2.56e-05	0.000277	CcSEcCtD
Ponatinib—FGFR4—Disease—FGFR3—testicular cancer	2.56e-05	0.000313	CbGpPWpGaD
Ponatinib—ABL1—Axon guidance—MMP2—testicular cancer	2.55e-05	0.000312	CbGpPWpGaD
Ponatinib—FGFR3—Disease—KITLG—testicular cancer	2.55e-05	0.000312	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—KIT—testicular cancer	2.55e-05	0.000312	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—FGFR3—testicular cancer	2.54e-05	0.000311	CbGpPWpGaD
Ponatinib—Rash—Methotrexate—testicular cancer	2.54e-05	0.000275	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—testicular cancer	2.54e-05	0.000275	CcSEcCtD
Ponatinib—SRC—Signaling by NGF—FGFR3—testicular cancer	2.53e-05	0.000309	CbGpPWpGaD
Ponatinib—Headache—Methotrexate—testicular cancer	2.52e-05	0.000273	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—testicular cancer	2.5e-05	0.000271	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—testicular cancer	2.49e-05	0.00027	CcSEcCtD
Ponatinib—SRC—Signaling Pathways—INSL3—testicular cancer	2.48e-05	0.000303	CbGpPWpGaD
Ponatinib—Pruritus—Doxorubicin—testicular cancer	2.47e-05	0.000267	CcSEcCtD
Ponatinib—FGFR2—Innate Immune System—FGFR3—testicular cancer	2.42e-05	0.000296	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—KITLG—testicular cancer	2.41e-05	0.000295	CbGpPWpGaD
Ponatinib—Vomiting—Epirubicin—testicular cancer	2.4e-05	0.000259	CcSEcCtD
Ponatinib—Nausea—Methotrexate—testicular cancer	2.39e-05	0.000259	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—testicular cancer	2.39e-05	0.000258	CcSEcCtD
Ponatinib—KIT—Innate Immune System—FGFR3—testicular cancer	2.38e-05	0.000291	CbGpPWpGaD
Ponatinib—Rash—Epirubicin—testicular cancer	2.38e-05	0.000257	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—testicular cancer	2.37e-05	0.000257	CcSEcCtD
Ponatinib—Headache—Epirubicin—testicular cancer	2.36e-05	0.000256	CcSEcCtD
Ponatinib—FGFR4—Disease—KIT—testicular cancer	2.35e-05	0.000288	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—KIT—testicular cancer	2.34e-05	0.000286	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—FGFR3—testicular cancer	2.33e-05	0.000285	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—KIT—testicular cancer	2.32e-05	0.000284	CbGpPWpGaD
Ponatinib—Dizziness—Doxorubicin—testicular cancer	2.31e-05	0.00025	CcSEcCtD
Ponatinib—KIT—Adaptive Immune System—FGFR3—testicular cancer	2.28e-05	0.00028	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—FGFR3—testicular cancer	2.26e-05	0.000276	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—FGFR3—testicular cancer	2.25e-05	0.000276	CbGpPWpGaD
Ponatinib—Nausea—Epirubicin—testicular cancer	2.24e-05	0.000242	CcSEcCtD
Ponatinib—FGFR2—Innate Immune System—KIT—testicular cancer	2.22e-05	0.000272	CbGpPWpGaD
Ponatinib—Vomiting—Doxorubicin—testicular cancer	2.22e-05	0.00024	CcSEcCtD
Ponatinib—Rash—Doxorubicin—testicular cancer	2.2e-05	0.000238	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—testicular cancer	2.2e-05	0.000238	CcSEcCtD
Ponatinib—LCK—Innate Immune System—KITLG—testicular cancer	2.19e-05	0.000268	CbGpPWpGaD
Ponatinib—Headache—Doxorubicin—testicular cancer	2.19e-05	0.000237	CcSEcCtD
Ponatinib—FGFR1—Adaptive Immune System—FGFR3—testicular cancer	2.17e-05	0.000265	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—FGFR3—testicular cancer	2.16e-05	0.000265	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—HPGDS—testicular cancer	2.15e-05	0.000263	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—KIT—testicular cancer	2.13e-05	0.000261	CbGpPWpGaD
Ponatinib—LCK—Immune System—BCL10—testicular cancer	2.12e-05	0.000259	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—KITLG—testicular cancer	2.1e-05	0.000257	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—MMP2—testicular cancer	2.08e-05	0.000255	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—KIT—testicular cancer	2.07e-05	0.000254	CbGpPWpGaD
Ponatinib—Nausea—Doxorubicin—testicular cancer	2.07e-05	0.000224	CcSEcCtD
Ponatinib—PDGFRA—Innate Immune System—KIT—testicular cancer	2.07e-05	0.000253	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—KIT—testicular cancer	1.99e-05	0.000244	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—FGFR3—testicular cancer	1.99e-05	0.000243	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—KIT—testicular cancer	1.98e-05	0.000243	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.98e-05	0.000242	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—FGFR3—testicular cancer	1.98e-05	0.000242	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—H2AFZ—testicular cancer	1.94e-05	0.000237	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—KITLG—testicular cancer	1.94e-05	0.000237	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—STK11—testicular cancer	1.93e-05	0.000236	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—FGFR3—testicular cancer	1.91e-05	0.000233	CbGpPWpGaD
Ponatinib—FGFR2—Disease—H2AFZ—testicular cancer	1.9e-05	0.000233	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—KITLG—testicular cancer	1.9e-05	0.000232	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—KIT—testicular cancer	1.88e-05	0.00023	CbGpPWpGaD
Ponatinib—SRC—Immune System—BCL10—testicular cancer	1.87e-05	0.000229	CbGpPWpGaD
Ponatinib—KIT—Disease—H2AFZ—testicular cancer	1.87e-05	0.000229	CbGpPWpGaD
Ponatinib—KIT—Immune System—KITLG—testicular cancer	1.86e-05	0.000228	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—KITLG—testicular cancer	1.86e-05	0.000228	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—MMP2—testicular cancer	1.86e-05	0.000228	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—MMP2—testicular cancer	1.83e-05	0.000224	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—KIT—testicular cancer	1.82e-05	0.000223	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—MMP2—testicular cancer	1.82e-05	0.000223	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—KIT—testicular cancer	1.81e-05	0.000222	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—FGFR3—testicular cancer	1.79e-05	0.000219	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KITLG—testicular cancer	1.78e-05	0.000218	CbGpPWpGaD
Ponatinib—FGFR1—Disease—H2AFZ—testicular cancer	1.78e-05	0.000217	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—H2AFZ—testicular cancer	1.77e-05	0.000217	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KITLG—testicular cancer	1.77e-05	0.000217	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KITLG—testicular cancer	1.76e-05	0.000216	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KITLG—testicular cancer	1.75e-05	0.000214	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—KIT—testicular cancer	1.75e-05	0.000214	CbGpPWpGaD
Ponatinib—FGFR3—Disease—KIT—testicular cancer	1.74e-05	0.000213	CbGpPWpGaD
Ponatinib—KIT—Disease—KITLG—testicular cancer	1.72e-05	0.000211	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—H2AFZ—testicular cancer	1.69e-05	0.000207	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—STK11—testicular cancer	1.68e-05	0.000206	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—KIT—testicular cancer	1.65e-05	0.000201	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KITLG—testicular cancer	1.63e-05	0.0002	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KITLG—testicular cancer	1.63e-05	0.000199	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—FGFR3—testicular cancer	1.63e-05	0.000199	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—FGFR3—testicular cancer	1.56e-05	0.000191	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—STK11—testicular cancer	1.56e-05	0.000191	CbGpPWpGaD
Ponatinib—LYN—Immune System—KITLG—testicular cancer	1.56e-05	0.00019	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KITLG—testicular cancer	1.55e-05	0.00019	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KITLG—testicular cancer	1.55e-05	0.00019	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—KIT—testicular cancer	1.49e-05	0.000183	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—FGFR3—testicular cancer	1.44e-05	0.000176	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—KIT—testicular cancer	1.43e-05	0.000176	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—HPGDS—testicular cancer	1.42e-05	0.000174	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—FGFR3—testicular cancer	1.41e-05	0.000173	CbGpPWpGaD
Ponatinib—KIT—Immune System—FGFR3—testicular cancer	1.39e-05	0.00017	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—FGFR3—testicular cancer	1.38e-05	0.000169	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—H2AFZ—testicular cancer	1.33e-05	0.000163	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—MMP2—testicular cancer	1.33e-05	0.000162	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—STK11—testicular cancer	1.33e-05	0.000162	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—KIT—testicular cancer	1.32e-05	0.000162	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—FGFR3—testicular cancer	1.31e-05	0.000161	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—FGFR3—testicular cancer	1.31e-05	0.000161	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—H2AFZ—testicular cancer	1.31e-05	0.00016	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—STK11—testicular cancer	1.3e-05	0.000159	CbGpPWpGaD
Ponatinib—FGFR2—Disease—FGFR3—testicular cancer	1.3e-05	0.000159	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—KIT—testicular cancer	1.29e-05	0.000159	CbGpPWpGaD
Ponatinib—LCK—Disease—H2AFZ—testicular cancer	1.28e-05	0.000157	CbGpPWpGaD
Ponatinib—KIT—Disease—FGFR3—testicular cancer	1.28e-05	0.000157	CbGpPWpGaD
Ponatinib—LCK—Immune System—KITLG—testicular cancer	1.28e-05	0.000156	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—KIT—testicular cancer	1.27e-05	0.000156	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—H2AFZ—testicular cancer	1.24e-05	0.000152	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—H2AFZ—testicular cancer	1.24e-05	0.000152	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STK11—testicular cancer	1.24e-05	0.000151	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STK11—testicular cancer	1.23e-05	0.000151	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KITLG—testicular cancer	1.23e-05	0.00015	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KIT—testicular cancer	1.22e-05	0.000149	CbGpPWpGaD
Ponatinib—FGFR1—Disease—FGFR3—testicular cancer	1.21e-05	0.000149	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—FGFR3—testicular cancer	1.21e-05	0.000148	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KIT—testicular cancer	1.21e-05	0.000148	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KITLG—testicular cancer	1.2e-05	0.000148	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KIT—testicular cancer	1.2e-05	0.000147	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KIT—testicular cancer	1.2e-05	0.000146	CbGpPWpGaD
Ponatinib—LCK—Disease—KITLG—testicular cancer	1.18e-05	0.000144	CbGpPWpGaD
Ponatinib—LYN—Immune System—FGFR3—testicular cancer	1.16e-05	0.000142	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—FGFR3—testicular cancer	1.15e-05	0.000141	CbGpPWpGaD
Ponatinib—ABL1—Immune System—FGFR3—testicular cancer	1.15e-05	0.000141	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KITLG—testicular cancer	1.14e-05	0.00014	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KITLG—testicular cancer	1.14e-05	0.00014	CbGpPWpGaD
Ponatinib—SRC—Disease—H2AFZ—testicular cancer	1.13e-05	0.000139	CbGpPWpGaD
Ponatinib—SRC—Immune System—KITLG—testicular cancer	1.13e-05	0.000138	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KIT—testicular cancer	1.11e-05	0.000136	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KIT—testicular cancer	1.11e-05	0.000136	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—H2AFZ—testicular cancer	1.09e-05	0.000134	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STK11—testicular cancer	1.09e-05	0.000133	CbGpPWpGaD
Ponatinib—LYN—Immune System—KIT—testicular cancer	1.06e-05	0.00013	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KIT—testicular cancer	1.06e-05	0.00013	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KIT—testicular cancer	1.06e-05	0.000129	CbGpPWpGaD
Ponatinib—SRC—Disease—KITLG—testicular cancer	1.04e-05	0.000128	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—STK11—testicular cancer	1.03e-05	0.000126	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—HPGDS—testicular cancer	1.02e-05	0.000125	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KITLG—testicular cancer	1.01e-05	0.000123	CbGpPWpGaD
Ponatinib—LCK—Immune System—FGFR3—testicular cancer	9.48e-06	0.000116	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—FGFR3—testicular cancer	9.12e-06	0.000112	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—H2AFZ—testicular cancer	8.96e-06	0.00011	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—FGFR3—testicular cancer	8.96e-06	0.00011	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STK11—testicular cancer	8.91e-06	0.000109	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—HPGDS—testicular cancer	8.82e-06	0.000108	CbGpPWpGaD
Ponatinib—LCK—Disease—FGFR3—testicular cancer	8.75e-06	0.000107	CbGpPWpGaD
Ponatinib—LCK—Immune System—KIT—testicular cancer	8.7e-06	0.000107	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—FGFR3—testicular cancer	8.5e-06	0.000104	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—FGFR3—testicular cancer	8.48e-06	0.000104	CbGpPWpGaD
Ponatinib—SRC—Immune System—FGFR3—testicular cancer	8.39e-06	0.000103	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KIT—testicular cancer	8.37e-06	0.000102	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KITLG—testicular cancer	8.25e-06	0.000101	CbGpPWpGaD
Ponatinib—LCK—Disease—KIT—testicular cancer	8.04e-06	9.84e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—H2AFZ—testicular cancer	7.94e-06	9.71e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STK11—testicular cancer	7.89e-06	9.66e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KIT—testicular cancer	7.8e-06	9.55e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KIT—testicular cancer	7.78e-06	9.53e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—FGFR3—testicular cancer	7.75e-06	9.48e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KIT—testicular cancer	7.7e-06	9.43e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—HPGDS—testicular cancer	7.68e-06	9.41e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—FGFR3—testicular cancer	7.48e-06	9.15e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—STK11—testicular cancer	7.4e-06	9.06e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KITLG—testicular cancer	7.3e-06	8.94e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HPGDS—testicular cancer	7.24e-06	8.86e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KIT—testicular cancer	7.11e-06	8.71e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KIT—testicular cancer	6.86e-06	8.4e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—STK11—testicular cancer	6.41e-06	7.84e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FGFR3—testicular cancer	6.13e-06	7.5e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KIT—testicular cancer	5.63e-06	6.89e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—STK11—testicular cancer	5.58e-06	6.83e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGFR3—testicular cancer	5.43e-06	6.64e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—STK11—testicular cancer	5.26e-06	6.44e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KIT—testicular cancer	4.98e-06	6.1e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HPGDS—testicular cancer	4.73e-06	5.79e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—STK11—testicular cancer	3.44e-06	4.21e-05	CbGpPWpGaD
